Pictet Asset Management Holding SA Cuts Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Pictet Asset Management Holding SA reduced its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 2.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 112,089 shares of the company’s stock after selling 3,261 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Krystal Biotech were worth $17,560,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. Wilmington Savings Fund Society FSB purchased a new stake in shares of Krystal Biotech during the 3rd quarter valued at $40,000. Avanza Fonder AB bought a new position in Krystal Biotech in the fourth quarter valued at $119,000. KBC Group NV lifted its stake in Krystal Biotech by 46.3% during the fourth quarter. KBC Group NV now owns 939 shares of the company’s stock worth $147,000 after purchasing an additional 297 shares during the last quarter. Blue Trust Inc. boosted its holdings in shares of Krystal Biotech by 74.4% in the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock worth $159,000 after purchasing an additional 433 shares in the last quarter. Finally, US Bancorp DE increased its position in shares of Krystal Biotech by 8.7% during the 4th quarter. US Bancorp DE now owns 1,027 shares of the company’s stock valued at $161,000 after purchasing an additional 82 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Price Performance

NASDAQ KRYS opened at $174.58 on Wednesday. Krystal Biotech, Inc. has a 1 year low of $141.72 and a 1 year high of $219.34. The stock has a market capitalization of $5.03 billion, a PE ratio of 58.39 and a beta of 0.87. The business’s 50-day moving average is $171.92 and its 200 day moving average is $173.26.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business’s quarterly revenue was up 116.4% compared to the same quarter last year. During the same period last year, the company earned $0.30 EPS. As a group, equities research analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Buying and Selling at Krystal Biotech

In other news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the sale, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on KRYS shares. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. Chardan Capital upped their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. HC Wainwright reaffirmed a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a report on Friday, February 28th. Citigroup boosted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. Finally, Jefferies Financial Group initiated coverage on Krystal Biotech in a research note on Wednesday, March 5th. They set a “buy” rating and a $245.00 price objective on the stock. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $220.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).